William E. Evans
Impact in
- Pharmacology top 0.01%
- Pharmacogenetics and Drug Metabolism
- Hematology top 0.05%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Papers in
-
- Acute Lymphoblastic Leukemia research 207
-
- Childhood Cancer Survivors' Quality of Life 81
- Pharmaceutical studies and practices 32
- Co-authors
- Mary V. Relling (171 shared papers)Ching‐Hon Pui (123 shared papers)Howard L. McLeod (9 shared papers)Eugene Y. Krynetski (29 shared papers)Gaston K. Rivera (43 shared papers)Cheng Cheng (42 shared papers)John T. Sandlund (38 shared papers)James R. Downing (24 shared papers)
- Journals
- Blood (52 papers)Journal of Clinical Oncology (30 papers)Clinical Pharmacology & Therapeutics (28 papers)New England Journal of Medicine (9 papers)The Journal of Pediatrics (8 papers)
- Partner nations
- United StatesGermanyNetherlands
In The Last Decade
William E. Evans
381 papers receiving 36.6k citations
William E. Evans's Hit Papers
Peers
Comparison fields: 5 of 202
- Pharmacology 6.1k
- Hematology 7.3k
- Public Health, Environmental and Occupational Health 16.1k
- Pediatrics, Perinatology and Child Health 9.4k
- Oncology 6.3k
Countries citing papers authored by William E. Evans
This map shows the geographic impact of William E. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William E. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William E. Evans more than expected).
Fields of papers citing papers by William E. Evans
This network shows the impact of papers produced by William E. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William E. Evans. The network helps show where William E. Evans may publish in the future.
Co-authors
The 25 scholars most cited alongside William E. Evans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 398 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics Hit paper breakdown → | 1999 | 1960 |
| 2 | Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling Hit paper breakdown → | 2002 | 1508 |
| 3 | Treatment of Acute Lymphoblastic Leukemia Hit paper breakdown → | 2006 | 1491 |
| 4 | Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects Hit paper breakdown → | 2003 | 1382 |
| 5 | Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia Hit paper breakdown → | 2007 | 1320 |
| 6 | Applied pharmacokinetics : principles of therapeutic drug monitoring Hit paper breakdown → | 1992 | 701 |
| 7 | Acute Lymphoblastic Leukemia Hit paper breakdown → | 1998 | 687 |
| 8 | A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study Hit paper breakdown → | 2009 | 650 |
| 9 | Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration Hit paper breakdown → | 2015 | 632 |
| 10 | Pharmacogenomics in the clinic Hit paper breakdown → | 2015 | 619 |
| 11 | Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia Hit paper breakdown → | 1991 | 590 |
| 12 | Moving towards individualized medicine with pharmacogenomics Hit paper breakdown → | 2004 | 568 |
| 13 | Pharmacogenomics and Individualized Drug Therapy Hit paper breakdown → | 2005 | 543 |
| 14 | 2004 | 473 | |
| 15 | Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing Hit paper breakdown → | 2011 | 448 |
| 16 | Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on Hit paper breakdown → | 2018 | 442 |
| 17 | 1998 | 410 | |
| 18 | Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Hit paper breakdown → | 2012 | 384 |
| 19 | Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers Hit paper breakdown → | 2014 | 379 |
| 20 | 2009 | 368 |
About William E. Evans
William E. Evans is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health, Molecular Biology, Oncology and Hematology, having authored 398 papers that have together received 38.5k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (207 papers), Childhood Cancer Survivors' Quality of Life (81 papers), Pharmacogenetics and Drug Metabolism (34 papers), Acute Myeloid Leukemia Research (33 papers), Pharmaceutical studies and practices (32 papers), Cancer therapeutics and mechanisms (29 papers), Cancer Treatment and Pharmacology (21 papers) and Chronic Myeloid Leukemia Treatments (20 papers). The work is most often cited by research in Pharmacology (6.1k citations), Hematology (7.3k citations), Public Health, Environmental and Occupational Health (16.1k citations), Pediatrics, Perinatology and Child Health (9.4k citations) and Oncology (6.3k citations). William E. Evans has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Mary V. Relling, Ching‐Hon Pui, Howard L. McLeod, Eugene Y. Krynetski, Gaston K. Rivera, Cheng Cheng, John T. Sandlund, James R. Downing, Raul C. Ribeiro and Wenjian Yang. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Pharmacology & Therapeutics, New England Journal of Medicine and The Journal of Pediatrics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.